An interventional study of 5A organizational innovation in Smoking Cessation and Pregnancy Related, sponsored by University Hospital, Bordeaux. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-25.
Sponsored by University Hospital, Bordeaux · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Smoking Cessation with a site in France — 8 open to participants now, 11 under way, 1 of them phase 3. Smoking Cessation · France.
Among the 48 studies in Smoking Cessation with a site in France, this one is the 2nd largest by planned enrollment of the 43 interventional ones that give a count, is one of 6 that started in 2022, is one of 21 with no phase, reaches primary completion later than 1 of the 10 other live ones, and was the 37th registered.
1,583 studies on the registry are indexed under Smoking Cessation; 196 are open to participants now.
Browse Smoking Cessation studies →8 of the 48 studies in Smoking Cessation with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 50–74
Institut du Cancer de Montpellier - Val d'Aurelle · Sites in France
Ages 18+
Groupe Hospitalier Mutualiste de Grenoble · Sites in France
Ages 18+
Poitiers University Hospital · Sites in France
Ages 18+
Poitiers University Hospital · Sites in France
Ages 18–25
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 134 Smoking Cessation studies recruiting now, 92 (69%) set no upper age limit and 35 (26%) stop at 75 or younger; 6 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 6 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 4,505 is above the median of 163 across 1,425 interventional studies indexed under Smoking Cessation.
Median enrollment 124 across the 43 interventional studies, 112 across the 5 observational. Of the 34 that completed or were terminated, 6 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 48 have an industry lead sponsor. The 10 most frequent:
University Hospital, Bordeaux is the lead sponsor of 807 studies on the registry; 198 are open to participants now.
University Hospital, Bordeaux has 1 study filed under Smoking Cessation — fewer than ten, so there is no comparison to draw.
3 of the studies in Smoking Cessation with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06910566Centre Oscar LambretFactors Sustaining Tobacco Abstinence in Cancer Patients Treated With Radio-chemotherapy or Radiotherapy | 2026-11 |
| NCT06988644Groupe Hospitalier Mutualiste de GrenobleImpact of a Counseling Consultation in the Workplace for Smoker Health Professionals | 2026-11-30 |
| NCT07198971Institut du Cancer de Montpellier - Val d'AurelleFeasibility Study Incorporating Music Therapy to Optimise the Smoking Cessation Process Coordinated by a Tobacco Addiction Nurse in Smoking Patients Being Treated for Cancer | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 48 studies in Smoking Cessation with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators are conducting a pragmatic cluster randomized trial in stepped-wedge of which objectives are to evaluate the effectiveness and the conditions of effectiveness of an organizational strategy for smoking cessation - 5A-QUIT-N - among pregnant women in New Aquitaine (NA), by using and optimizing existing resources
In France, in 2016, 16.6% of pregnant women were smokers, the highest levels among European countries. Pregnancy is considered a teachable moment for smoking cessation. There are many tools, interventions and programs to reduce the smoking habits of pregnant women. The challenge is therefore not to propose new interventions but to understand what is hindering the implementation of existing interventions and proposing corrective measures. In this context, the scientific literature shows that interventions for smoking pregnant women only seem effective when based on a comprehensive approach that combines multiple interventions. In particular, interventions based on the 5A's model (Ask, Advise, Assess, Assist, Arrange) are largely recommended and have shown their effectiveness abroad. Factors facilitating or hindering the implementation of such strategies are mainly organizational. As organizations are context-dependent by nature, considering the generalization of such strategies in France therefore requires adapting them to the French health system and evaluating them in context, in a pragmatic approach, inserted into routine care and using the tools, procedures and existing organizations in the territories.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In this research, there are 4 categories of research participants:
Inclusion criteria for the intervention
The inclusion criteria for the clusters are :
The inclusion criteria for care providers within the clusters are:
The inclusion criteria for pregnant women within the clusters are :
Inclusion criteria for the primary objective measures:
The inclusion criteria for women are (for data collection):
Non-inclusion criteria for the intervention
Cluster non-inclusion criteria:
Non-inclusion criteria of measures for the primary objective:
The criteria for non-inclusion of women who have just given birth are:
The 5A-QUIT-N intervention can be defined as multilevel, i.e., it is based on a territorial organization with expected results at the level of professional practice (structuring of practices around the 5A method) and therefore of the care of pregnant women who smoke tobacco. This project is based on three strategic axes: * A gradation of the care offer * Personalized care by developing specific treatment paths * Coordination of territorial resources to support pregnant women in quitting smoking. These elements will make it possible to propose a partnership-based, multi-professional, coordinated and integrated approach to the territory, supported by the technical resources and expertise available in the territory. It invites a majority of non-specialized actors to invest in the process of supporting pregnant women in quitting smoking, multiplying and potentiating their actions with this population.
Other: 5A organizational innovation
Usual care in the care of pregnant women who smoke tobacco.
This project is based on three strategic axes: * A gradation of the care offer allowing to adapt the means and resources mobilized on the territory * Personalized care by developing specific treatment paths based on the risk factors and/or vulnerabilities of the pregnant woman * Coordination of territorial resources to support pregnant women in quitting smoking These three key elements will make it possible to propose a partnership-based, multi-professional, coordinated and integrated approach to the territory, supported by the technical resources and expertise available in the territory. It invites a majority of non-specialized actors to invest in the process of supporting pregnant women in quitting smoking, multiplying and potentiating their actions with this population.
Tobacco abstinence at delivery
The point prevalence of abstinence at delivery, which is the proportion of women reporting abstinence from smoking for at least 7 days at delivery. This criterion is well documented in the literature assessing tobacco use. It has the advantage of detecting the delayed effects of an intervention and can be easily extrapolated.
Time frame: At delivery (smoking status of the previous 7 days)
Average number of cigarettes smoked at inclusion
Average number of cigarettes smoked per day over the last 30 (or 7) days
Time frame: At inclusion
Average number of cigarettes smoked at postpartum
Average number of cigarettes smoked per day over the last 30 (or 7) days
Time frame: 6 months and 1 year after delivery
Attempts to reduce tobacco consumption
The number of attempts to reduce tobacco consumption (at least 1 cigarette)
Time frame: 1 to 3 days after delivery
Attempts to quit smoking
Number of attempts to quit smoking (at least 24 hours)
Time frame: 1 to 3 days after delivery
Continuous abstinence
Continuous abstinence (in number of days)
Time frame: 1 to 3 days after delivery
Birth weight
Birth weight (in kg) of the baby
Time frame: At baby birth, up to 3 days after delivery
Gestational age
Gestational age (in months) of the baby (at birth).
Time frame: At baby birth, up to 3 days after delivery
Sustainability of professional practices
Prevalence of completion of each A of the 5A approach evaluated on a subgroup of women who have just given birth at a distance from the deployment of the intervention (18 months) via the questionnaire
Time frame: 18 months from the deployment of the intervention
Sustainability of the impact on health
Prevalence of women smoking tobacco at delivery over the last 7 days via two sources: the computer systems of the maternity units that have this information systematically (non-exhaustive because not all maternity units in the New Aquitaine region have a computer system) and on a sub-group of women who have just given birth
Time frame: 18 months from the deployment of the intervention
Postpartum relapse rate at 6 months
Relapse rate among women who quit smoking during pregnancy at 6 and 12 months postpartum defined as a resumption of at least 7 consecutive days of smoking in the past 6 months.
Time frame: At 6 months postpartum
Postpartum relapse rate at 12 months
Relapse rate among women who quit smoking during pregnancy at 6 and 12 months postpartum defined as a resumption of at least 7 consecutive days of smoking in the past 6 months.
Time frame: At 12 months postpartum
Continued abstinence
Continued abstinence (in number of days)
Time frame: 6 months and 1 year after delivery
Implementation of intervention
Barriers and levers to implementation in professionals
Time frame: Through study completion, an average of 3 years
Conditions of transferability
Conditions of transferability linked to the characteristics of the stakeholders and the context: contextual conditions for success within the centres, the characteristics of professionals and patients influencing outcomes
Time frame: Through study completion, an average of 3 years
Viability
Assessment of intervention deployment in a real-world setting, using 5 criteria: utility, affordability, evaluability, adaptability and acceptability. "Utility" dimension (as a complement to the secondary criteria) of viability through the recovery mechanisms identified as successful mental health recovery Affordability for professionals and beneficiaries (financial, geographical, social and cultural levers and brakes of the intervention) Evaluability of 5A-QUIT-N: carrying out this evaluation, the availability of professionals and beneficiaries to answer questionnaires and interviews, missing data in the questionnaires etc. Adaptability of 5A-QUIT-N: integration of the action into the context and the current organisation of the centres Acceptability of 5A-QUIT-N: by professionals and beneficiaries
Time frame: Through study completion, an average of 3 years
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2022 (actual). Primary completion is estimated for May 2025, 31 months after the start.
Of 547 non-industry interventional studies with no phase under Smoking Cessation, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's planned 31 months is above that.
Counting every sponsor, half of 564 studies reached it within 24 months; a quarter within 12 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Bordeaux →